Neuronal nicotinic acetylcholine receptors (nAChRs) are promising drug targets to manage several neurological disorders and nicotine addiction. Growing evidence indicates that positive allosteric modulators of nAChRs improve pharmacological specificity by binding to unique sites present only in a subpopulation of nAChRs. Furthermore, nAChR positive allosteric modulators such as NS9283 and CMPI have been shown to potentiate responses of (␣4)3(␤2)2 but not (␣4)2(␤2)3 nAChR isoforms. This selective potentiation underlines that the ␣4:␣4 interface, which is present only in the (␣4)3(␤2)2 nAChR, is an important and promising drug target. In this report we used site-directed mutagenesis to substitute specific amino acid residues and computational analyses to elucidate CMPI's binding mode at the ␣4:␣4 subunit extracellular interface and identified a unique set of amino acid residues that determined its affinity. We found that amino acid residues ␣4Gly-41, ␣4Lys-64, and ␣4Thr-66 were critical for (␣4)3(␤2)2 nAChR potentiation by CMPI, but not by NS9283, whereas amino acid substitution at ␣4His-116, a known determinant of NS9283 and of agonist binding at the ␣4:␣4 subunit interface, did not reduce CMPI potentiation. In contrast, substitutions at ␣4Gln-124 and ␣4Thr-126 reduced potentiation by CMPI and NS9283, indicating that their binding sites partially overlap. These results delineate the role of amino acid residues contributing to the ␣4:␣4 subunit extracellular interface in nAChR potentiation. These findings also provide structural information that will facilitate the structure-based design of novel therapeutics that target selectively the (␣4)3(␤2)2 nAChR.
Drugs that enhance the function of brain nicotinic acetylcholine receptors (nAChRs) 3 are sought for their potential clinical applications in the management of nicotine dependence (tobacco smoking) and for improvement of cognitive deficits associated with neurological and psychiatric disorders (1) . However, it has proven challenging to develop nAChR therapeutics selective for nAChR subtypes, and few are available clinically (2) . Neuronal nAChRs are transmitter (ACh)-gated ion channels made up of five homologous or identical subunits (␣2-␣9 and ␤2-␤4), each one consisting of a large N-terminal extracellular domain and a 4-helix bundle transmembrane domain. The recently published X-ray structure of (␣4)2(␤2)3 nAChR confirmed this general subunit topology and provided further insight into the 3D structure of neuronal nAChRs (3) . Whereas there are multiple neuronal nAChR subtypes with unique pathophysiological and pharmacological profiles, the ␣4and ␤2-containing nAChR subtypes are of particular interest (4, 5) . They constitute the majority of brain nAChRs (6) and are the primary nAChR subtypes that mediate the addictive effects of nicotine (7, 8) . In addition, they are important for neuronal survival and maintenance of cognitive performance and learning during aging (9) , and there is a decrease in their number in the brain of Alzheimer's patients (10) .
Drugs that enhance signaling through nAChRs include agonists and partial agonists that bind to the orthosteric (ACh) binding sites and directly activate the nAChR and positive allosteric modulators (PAM) that enhance ACh potency and/or efficacy by binding at sites distinct from the ACh-binding sites (11) . Many years of effort have defined the ACh-binding sites at subunit interfaces within the extracellular domain and determined structural requirements for nAChR agonists (12) . In contrast, compounds with diverse structural features potentiate nAChRs (1) , and multiple PAM recognition sites have been proposed. These include pockets at the extracellular canonical (agonist-binding) and non-canonical subunit interfaces (13) (14) (15) (16) (17) , within the transmembrane domain in the helix bundle of a single subunit (18) , at the interface between adjacent subunits (19) , and at the subunit's extracellular C-tail (20 -21) . There is an increasing interest in the development of novel nAChR PAMs, as they provide potentially selective modulation of a subpopulation of nAChRs while avoiding the sustained receptor activation and non-physiological alteration in cholinergic transmission seen with agonists (11, 22) .
Neuronal nAChRs consisting of the ␣4 and ␤2 subunits, alone or with additional nAChR subunits, exist in two pharmacologically distinct isoforms (Fig. 1. A and B) (23) (24) . The (␣4)2(␤2)3 nAChR exhibits high sensitivity for ACh and other nAChR agonists (ACh EC 50 ϳ1 M), whereas the (␣4)3(␤2)2 nAChR has lower sensitivity for ACh and other nAChR agonists (ACh EC 50 ϳ100 M). Although both isoforms have AChbinding sites at the two agonist-binding "canonical" ␣4:␤2 extracellular interfaces, recent findings establish the presence of a low-affinity ACh-binding site within the "non-canonical" ␣4:␣4 extracellular interface, which is present only in the (␣4)3(␤2)2 nAChR isoform (25) (26) (27) . In addition to altering agonist sensitivity, the ␣4:␣4 subunit interface in the (␣4)3 (␤2)2 nAChR confers selectivity to nAChR PAMs (28 -30) .
Here, we expand these studies to identify the amino acid residues at the ␣4:␣4 subunit interface that are important for (␣4)3(␤2)2 nAChR potentiation by CMPI ( Fig. 1C; 3 -(2chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4yl)isoxazole), a potent nAChR PAM that potentiates (␣4)3 (␤2)2 but not (␣4)2(␤2)3 nAChR (30, 31) . We express (␣4)3(␤2)2 nAChR, wild-type or containing amino acid substitutions, in Xenopus laevis oocytes and use two-electrode voltage-clamp recordings to assess the effect of these substitutions on (␣4)3(␤2)2 nAChR modulation by CMPI, NS9283 (3-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]benzonitrile, another PAM that also requires the presence of ␣4:␣4 interface for potentiation; Refs. 17 and 32) , and desformylflustrabromine (dFBr, a PAM of (␣4)3(␤2)2 and (␣4)2(␤2)3 nAChRs (33, 34) ).
Results
Previous studies have established dFBr, CMPI, and NS9283 as potent nAChR PAMs with high selectivity for the ␣4-con-taining nAChRs (28, 31, 35) . In addition, the effects of dFBr, CMPI and NS9283 on high-and low-agonist sensitivity isoforms of ␣4␤2 nAChR have been examined by recording AChinduced currents from Xenopus oocytes injected with ␣4 and ␤2 subunits RNAs at ratios that favor the expression of (␣4)3(␤2)2 or (␣4)2(␤2)3 nAChR. dFBr potentiated both ␣4␤2 nAChR isoforms, whereas NS9283 and CMPI potentiated (␣4)3(␤2)2 (low sensitivity) nAChR but not (␣4)2(␤2)3 (high sensitivity) nAChR (17, 30) . As shown in Fig. 2A , co-application of 1 M CMPI, NS9283, or dFBr with ACh enhanced AChinduced current responses of Xenopus oocytes expressing (␣4)3(␤2)2 nAChR. In contrast, ACh-induced current responses of (␣4)2(␤2)3 nAChR were enhanced by co-application of dFBr but not CMPI or NS9283 (Fig. 2B ). Coapplication of CMPI or NS9283 at concentrations up to 10 M did not enhance (␣4)2(␤2)3 nAChR current responses to 1, 3, or 10 M ACh (data not shown).
Effect of amino acid substitutions at the ␣4:␣4 subunit extracellular interface on modulation by CMPI
The stoichiometry dependence of enhancement by NS9283 and CMPI underscores an essential role in nAChR allosteric modulation of the non-canonical ␣4:␣4 subunit interface, which is present only in the (␣4)3(␤2)2 nAChR. It also indicates the presence of at least two classes of PAM-binding sites within the ␣4␤2 nAChR: one (or more) at the ␣4:␣4 subunit interface that mediates the effect of NS9283 and CMPI and one (or more) at the ␣4:␤2 and/or ␤2:␣4 subunit interfaces that mediates the effect of dFBr. Indeed, a histidine-to-valine substitution at posi- Figure 1 . A, top view of the X-ray structure of human (␣4)2(␤2)3 nAChRs (PDB accession number 5KXI). B, top view of a homology model of an (␣4) 3 (␤2) 2 nAChR based on the crystal structure of (␣4)2(␤2)3 nAChRs. C, chemical structure of nAChRs PAMs: NS9283 and CMPI.
Figure 2. Representative traces showing the effects of CMPI, NS9283, and dFBr on ACh-induced current responses of (␣4)3(␤2)2 (A) and (␣4)2(␤2)3 (B) nAChRs, respectively.
Xenopus oocytes expressing wild type human (␣4)3(␤2)2 or (␣4)2(␤2)3 nAChRs were voltage-clamped at Ϫ50 mV, and currents elicited by 10-s applications of 10 M ACh were recorded in the absence or presence of 1 or 3 M CMPI, NS9283, or dFBr. tion ␣4His-116 (␣4His-142 when numbering includes the signal peptide), which projects into the ␣4:␣4 subunit extracellular interface, significantly reduced NS9283 potentiation of (␣4)3(␤2)2 nAChRs (32) . Because CMPI does not potentiate (␣4)2(␤2)3 or (␣3)3(␤2)2 nAChR, we reasoned that amino acid substitutions making the ␣4 subunit more similar to the ␣3 or ␤2 subunit will lead to identification of amino acid residues that confer CMPI selectivity to (␣4)3(␤2)2 nAChR and test the possibility that NS9283 and CMPI share the same determinants for potentiation.
The non-canonical ␣4:␣4 subunit extracellular interface is made up of amino acid residues from a (ϩ) face of one ␣4 subunit and a (Ϫ) face of the adjacent ␣4 subunit. The ␣4 subunit (ϩ) face is also present at the canonical ␣4:␤2 interface where it provides the core aromatic residues of the agonistbinding sites, whereas the ␣4 subunit (Ϫ) face is also at the ␤2:␣4 interface present in the (␣4)2(␤2)3 and (␣4)3(␤2)2 nAChRs. Based on amino acid sequence alignments of ␣4, ␤2, and ␣3 subunits and a homology model of the (␣4)3(␤2)2 nAChR ( Fig. 3 ), 10 non-conserved amino acid residues within the ␣4 subunit (Ϫ) face that project into the ␣4:␣4 extracellular interface were identified and substituted to the corresponding amino acid residues in the ␤2 and/or ␣3 subunit.
The effects of these amino acid substitutions were assessed by recording ACh-induced current responses (Ϯ CMPI, NS9283, or dFBr) of Xenopus oocytes injected with a mix of RNA encoding ␣4 containing the point mutation and WT ␤2 subunit RNA at a ratio of 8:1 to favor the expression of the 3␣4:2␤2 stoichiometry (Fig. 4A ). The potentiation for each amino acid substitution was determined as R, the ratio of the peak current amplitude in the presence of 1 M PAM and 10 M ACh (EC 10 ) relative to the peak current amplitude elicited by 10 M ACh alone (Table 1) . Consistent with previous reports (17, 32) , valine substitution at ␣4His-116 (␣4H116V) abolished the enhancement by 1 M NS9283 (R H116V ϭ 1.1 Ϯ 0.1 versus R WT ϭ 3.8 Ϯ 0.3). In contrast, the ␣4H116V substitution did not reduce enhancement by CMPI (R H116V ϭ 5.3 Ϯ 0.4 versus R WT ϭ 4.3 Ϯ 0.4) or dFBr (R H116V ϭ 5.9 Ϯ 0.4 versus R WT ϭ 5.1 Ϯ 0.4). Similar effects were seen for CMPI in receptors harboring ␣4H116L or ␣4H116A substitutions (Table 1) , which indicates that the position ␣4His-116 is not essential for CMPI or dFBr modulation of (␣4)3(␤2)2 nAChR.
In contrast to ␣4His-116, for (␣4)3(␤2)2 nAChRs containing ␣4G41M, ␣4K64T, or ␣4E66I mutant subunits, potentiation by NS9283 was unaffected, whereas potentiation by CMPI was reduced to Ͻ1.5-fold that for 10 M ACh alone (Table 1) . These results establish a selective role of ␣4Gly-41, ␣4Lys-64, and ␣4Glu-66 in CMPI potentiation of the (␣4)3(␤2)2 nAChR.
The substitution ␣4Q124T reduced potentiation by either CMPI or NS9283 at 1 M to ϳ2 and 1.6, respectively, whereas the substitution ␣4T126I reduced potentiation to ϳ1.2 and 1, respectively. However, at 10 M, NS9283, but not CMPI, potentiated ACh current responses of (␣4Q124F)3(␤2)2 and (␣4T126L)3(␤2)2 nAChRs by 4.3 Ϯ 0.2-and 1.73 Ϯ 0.1-fold, respectively ( Fig. 4B ). Thus, positions ␣4Gln-124 and ␣4Thr-126 contribute to (␣4)3(␤2)2 nAChR potentiation by CMPI and NS9283 but are more important for CMPI than NS9283.
Amino acid substitutions at positions ␣4Leu-37, ␣4Arg-39, ␣4His-68, and ␣4Arg-122 had no significant effect (p Ͻ 0.001) on CMPI or NS9283 potentiation (Table 1) , indicating a minimal role, if any, of these amino acid residues in CMPI or NS9283 potentiation of (␣4)3(␤2)2 nAChR. None of the tested amino acid substitutions within the ␣4(Ϫ) extracellular interface had a significant effect on dFBr potentiation of (␣4)3(␤2)2 nAChR ( Table 1) .
Effect of amino acid substitutions in the transmembrane domain on modulation by CMPI
Within the transmembrane domain, the ␣4:␣4 subunit interface is formed by amino acid residues from the M3 helix of the ␣4 subunit providing the (ϩ) face and residues from the M1 helix of the ␣4 subunit providing the (Ϫ) face as well as amino acid residues from M2 of both subunits. The ␣4 and ␣3 subunits share high amino acid sequence identity within M1-M2-M3, Figure 3 . A, side view of a homology model of an (␣4)3(␤2)2 nAChR showing amino acid residues contributing to the ␣4(Ϫ) face of the ␣4:␣4 extracellular interface. B, sequence alignments of amino acid contributing to the (Ϫ) face of the interface with corresponding regions in the ␤2 and ␣3 nAChR subunits. Amino acid numbering is for mature protein according to the X-ray structure of human (␣4)2(␤2)3 nAChRs (PDB accession number 5KXI). Add 26, 25, and 31 to ␣4, ␤2, and ␣3 sequence numbers, respectively, to obtain amino acid numbers starting from the translational N terminus. ␤-Strands in A are color-coded (␤1, cyan; ␤2, red; ␤5, blue; ␤6, green) to match their sequence alignments in B. Table 1 . Table 1 Modulation of WT and mutant (␣4)3(␤2)2 nAChRs by NS9283, CMPI, and dFBr Current responses to 10 M ACh, 10 M ACh ϩ1 M NS9283, 10 M ACh ϩ1 M CMPI, 10 M ACh ϩ1 M dFBr, and 1 mM ACh were recorded from oocytes expressing WT and mutant (␣4)3(␤2)2 nAChRs ( Fig. 4 ). -Fold potentiation in the presence of various PAMs was calculated as R, the ratio of peak current amplitude in the presence of 1 M PAM relative to peak current amplitude elicited by 10 M ACh alone from the same recording run. Replicas from the same oocyte were averaged. The data in the table are the average (Avg) Ϯ S.E. of several oocytes (N). The probability (P) that -fold potentiation differs from no potentiation (10 M AChϩPAM/10 M ACh ϭ 1) was analyzed using one-way analysis of variance with the Holm-Sidak test (SigmaPlot, Systat Software Inc.). R(NS9283), R(CMPI), and R(dFBr) values calculated for high sensitivity (␣4)2(␤2)3 nAChRs (n ϭ 4) were 1.0 Ϯ 0.1, 0.8 Ϯ 0.1, and 2.5 Ϯ 0.5, respectively.
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differing by one amino acid in M1 (␣4Cys-233), three amino acid residues in M2 (␣4Ile-249, ␣4Leu-265, and ␣4Ile-269), and one toward the cytoplasmic end of M3 (␣4His-306). Amino acid substitutions at positions ␣4Cys-233, ␣4Ile-249, ␣4Leu-265, and ␣4His-306 to the corresponding amino acid residues in the ␣3 subunit had no significant effect (p Ͻ 0.001) on CMPI or NS9283 potentiation (Table 1) .
CMPI concentration-dependent potentiation of WT and mutant (␣4)3(␤2)2 nAChRs
In WT (␣4)3(␤2)2 nAChR, co-application of CMPI maximally potentiated ACh current responses by ϳ400% with an EC 50 of ϳ0.3 M (30). We examined the effect of amino acid substitutions at the ␣4:␣4 extracellular interface on the concentration dependence of CMPI potentiation by recording current responses to 10 M ACh (EC 10 ) alone or in the presence of increasing concentrations of CMPI on oocytes expressing WT and mutant (␣4)3(␤2)2 nAChRs ( Fig. 5 ). For WT (␣4)3(␤2)2 nAChR, CMPI produced a maximal potentiation (I max ) of 386 Ϯ 15% with an EC 50 of 0.18 Ϯ 0.03 M ( Table 2) . For (␣4)3(␤2)2 nAChRs containing amino acid substitutions at positions ␣4Gly-41, ␣4Lys-64, ␣4Glu-66, ␣4Gln-124, or ␣4Thr-126, the observed current responses to 10 M ACh in the presence of CMPI at any concentration tested (0.01-3 M) was not significantly different from no CMPI ( Table 2 ). In contrast, for (␣4)3(␤2)2 nAChRs containing amino acid substitutions at positions ␣4Leu-37, ␣4Gln-39, ␣4His-68, ␣4His-116, or ␣4Arg-122, the values of I max for CMPI potentiation were significantly different from no CMPI (p Ͻ 0.001; Table 2 ). Indeed, the substitutions ␣4L37I, ␣4R39H, ␣4H116V, and ␣4H116V resulted in a higher CMPI I max than seen for WT. The CMPI EC 50 values for these mutants were not significantly different from that for WT (␣4)3(␤2)2 nAChR, consistent with no effect of amino acid substitution at ␣4Leu-37, ␣4Gln-39, ␣4His-68, ␣4His-116, or ␣4Arg-122 on the potency of CMPI as (␣4)3(␤2)2 nAChR potentiator.
The effect of CMPI on ACh concentration-response curves of WT and mutant (␣4)3(␤2)2 nAChRs
Recent reports support the presence of a low-affinity AChbinding site at the ␣4:␣4 subunit extracellular interface with substitutions of amino acid residues contributing to the ␣4:␣4 subunit extracellular interface altering the ACh concentrationresponse curve (25) (26) (27) . In view of this finding, we characterized ACh concentration responses for mutant (␣4)3(␤2)2 nAChRs in the absence and presence of CMPI by recording current responses to increasing concentrations of ACh alone and in the presence of 1 M CMPI from oocytes expressing WT and mutant (␣4)3(␤2)2 nAChRs (Fig. 6 ). The ACh concentration-response curve for WT (␣4)3(␤2)2 nAChR was characterized by an EC 50 of 99 Ϯ 23 M (Table 3 ). Co-application of 1 M CMPI produced a left shift of the ACh concentration-response curve, decreasing the ACh EC 50 to 0.6 Ϯ 0.2 M with little effect, if any, on the ACh maximum response (I max ϭ 98 Ϯ 4%). With the exception of the substitutions ␣4K64T, ␣4T126L, and ␣4T126I, the ACh concentration-response curves for mutant (␣4)3(␤2)2 nAChRs in the absence of CMPI were characterized by EC 50 values that were equal or slightly higher than that for WT ( Table 3 ). Co-application of 1 M CMPI with ACh to oocytes expressing (␣4)3(␤2)2 nAChRs containing amino acid substitutions at positions ␣4Leu-37, ␣4Arg-39, ␣4His-68, ␣4His-116, or ␣4Arg-122 produced a left shift of the ACh concentration-response curve significantly decreasing the ACh EC 50 (t test, p Ͻ 0.01). For oocytes expressing (␣4)3(␤2)2 showing the effect of increasing concentrations of CMPI on ACh-induced current responses of Xenopus oocytes expressing WT or mutant (␣4)3(␤2)2 nAChRs containing amino acid substitutions at the (Ϫ)face of ␣4 subunit. B, for each recording run, peak currents were normalized to the peak current elicited by 10 M ACh alone, replicas from individual oocytes were averaged, and the average Ϯ S.E. of data from several oocytes were plotted and fit (when possible) to a single-site model using Equation 1 . Parameters (potentiation EC 50 and I max ) are shown in Table 2 .
nAChRs containing amino acid substitutions at positions ␣4Gly-41, ␣4Lys-64, and ␣4Glu-66, CMPI did not significantly alter the ACh concentration-response curve when co-applied with ACh, and ACh EC 50 in the presence of 1 M CMPI and was not significantly different from that in the absence of CMPI. For (␣4T126L)3(␤2)2 and (␣4T126I)3(␤2)2 nAChRs, co-application of 1 M CMPI slightly potentiated current responses at low ACh concentrations (Ͻ10 M) and slightly decreased current responses at higher ACh concentrations, producing a less steep ACh concentration-response curve but with no significant decrease in the ACh EC 50 . For (␣4Q124F)3(␤2)2 and (␣4Q124T)3(␤2)2 nAChRs, the poorly defined maximum response resulted in a large degree of Table 2 CMPI modulation of WT and mutants (␣4)3(␤2)2 nAChRs Current responses to 10 M ACh alone or in the presence of increasing concentrations of CMPI were recorded from oocytes expressing WT and mutants (␣4)3(␤2)2 nAChRs. For each application peak current amplitude was quantified and normalized to peak current amplitude elicited by 10 M ACh alone within the same recording run. Replicas from the same oocyte were averaged and for each CMPI concentration (average (Avg) Ϯ S.E.) of data from several oocytes (N) were plotted ( Fig. 5 ) and fit to Equation 1. The probability (P) that an I max differs from no potentiation (I max ϭ 100) was analyzed using a one-way analysis of variance with the Holm-Sidak test. Curve-fitting, parameters calculation, and statistics were performed in SigmaPlot 11 (Systat Software Inc.). Currents elicited by Xenopus oocytes expressing WT and mutant (␣4)3(␤2)2 nAChRs in response to 10-s applications of increasing concentrations of ACh (alone (E) or ϩ1 M CMPI (F)) were recorded and normalized to peak currents elicited by 1 mM ACh alone. Replicas from the same oocyte were averaged, and the average Ϯ S.E. of data from several oocytes were plotted and fit to a single-site model using Equation 1 . Parameters (ACh EC 50 in the presence and absence of CMPI) are shown in Table 3 .
Subunits
uncertainty in ACh EC 50 calculation, and that precluded determination of any significant effect of CMPI on the ACh EC 50 .
ACh, CMPI, and NS9283 docking at the ␣4:␣4 extracellular interface
Structural studies, homology models based on available X-ray structures of AChBPs and pentameric ligand-gated ion channels, and the recently published X-ray structure of (␣4)2(␤2)3 nAChR (5) have identified unique features defining agonist binding at the ␣4:␤2 agonist-binding site (for review, see Refs. 12 and 36). The ␣4:␤2 agonist-binding site is delineated by five conserved aromatic amino acid residues forming a binding "pocket" for the trimethylammonium group of ACh: four from the ␣4 subunit (␣4Tyr-100, ␣4Trp-156, ␣4Tyr-197, ␣4Tyr-204) and one from the ␤2 subunit (␤2Trp-57). The ␤2 subunit provides additional amino acid residues (e.g. ␤2Val-111, ␤2Phe-119) that are not conserved among nAChR subunits. The non-canonical ␣4:␣4 subunit extracellular interface is structurally distinct from the ␣4:␤2 agonist-binding site and has a distinctive ligand selectivity imposed by amino acid residues in the complementary ␣4(Ϫ) face (27) .
In initial computational docking analyses visualizing the binding sites for CMPI and NS9283 (Fig. 7) , we used an (␣4)3(␤2)2 nAChR homology model based on the structure of Lymnaea AChBP crystallized in the presence of the agonist carbamylcholine (PDB accession number 1UV6; Ref. 37 ). Because we sought to perform docking analyses of CMPI and NS9283 in the absence and presence of ACh, we first docked ACh at the ␣4:␣4 extracellular interface (Fig. 7B) . The most favorable binding mode of ACh has a CDOCKER interaction energy of Ϫ31 kcal/mol with the nitrogen of the trimethylammonium group well coordinated by ␣4Tyr-100, ␣4Trp-156, ␣4Tyr-197, and ␣4Tyr-204 of the ␣4(ϩ) face and ␣4Trp-62 of the ␣4(-) face. The carbonyl group of the ACh is oriented toward the ␣4(Ϫ) face of the second ␣4 subunit, within 4.5 Å of ␣4His-116 (equivalent to ␤2Val-111, the main amino acid residue in the ␤2 subunit photolabeled by the agonist [ 3 H]epibatidine (38)), ␣4Gln-124, and ␣4Thr-126, and Ͼ7 Å from any other non-conserved residue in the ␣4(Ϫ) face.
In the absence of ACh, CMPI docked at the ␣4:␣4 subunit extracellular interface in one most favorable binding mode ( Fig.  7C) with CDOCKER interaction energy of Ϫ36.8 kcal/mol. In this orientation, the piperidine ring of the CMPI occupies the same location as the carbonyl group of ACh, with the CMPI long axis (length, 12.9 Å) extending outward between Segment C of the ␣4(ϩ) face and beta strands ␤6 (␣4Gln-124/␣4Thr-126), ␤2 (␣4Trp-62/␣4Lys-64), and ␤1 (␣4Gly-41/␣4Ser-43) of the adjacent ␣4(Ϫ) face. In contrast to CMPI, NS9283 in the absence of ACh docked with two equally favorable binding modes ( Fig. 7D) with CDOCKER interaction energies of Ϫ29.1 and Ϫ28.8 kcal/mol. In the first binding mode, NS9283 docked deep in the aromatic box with its long axis (length, 12.2 Å) extending upward adjacent to beta strands ␤5 and ␤6 of the ␣4(Ϫ) face. In the second binding mode, NS9283 maintained the same long axis orientation but was translocated 3Å closer to the ␣4(Ϫ) face. In both orientations, one end of NS9283 is within 4.0 Å of ␣4His-114, ␣4Gln-124, and ␣4Thr-126 of the ␣4(Ϫ) face.
When CMPI or NS9283 was docked at the ␣4:␣4 subunit extracellular interface in the presence of ACh (Fig. 7, E and F) , the lowest energy solutions for CMPI (Ϫ33.3 kcal/mol) and NS9283 (Ϫ29.7 kcal/mol) were superimposed along their long axes, with the benzonitrile of NS9283 and piperidine of CMPI within 4 Å of ␣4His-116. CMPI and NS9283 extend outward at the level of ␣4Gln-124 (6.6 and 3.1 Å, respectively) and ␣Glu-66 (11.5 and 5.2 Å, respectively).
In the course of writing this manuscript, the X-ray structure of the agonist-bound (␣4)2(␤2)3 nAChR was published (5) . Table 3 The effect of CMPI on ACh dose-response curve of (␣4)3(␤2)2 nAChRs Current responses to increasing concentrations of ACh (alone and in the presence of 1 M CMPI) were recorded from oocytes expressing WT and mutants (␣4)3(␤2)2 nAChRs. For each application, peak current amplitude was quantified and normalized to peak current amplitude elicited by 1 mM ACh alone within the same recording run. Replicas from individual oocytes were averaged. For each drug application (average Ϯ S.E.), data from several oocytes (N) were plotted ( Fig. 6 ) and fit to Equation 1. The probability (P) that the ACh EC 50 in the presence of CMPI differs from ACh EC 50 in the absence of CMPI was analyzed by t test. Curve-fitting and parameter calculation was performed in SigmaPlot 11 (Systat Software Inc.). One-way analysis of variance of ACh EC 50 values for WT and mutant (␣4)3(␤2)2 nAChRs in the absence of CMPI revealed no statistically significant difference (p ϭ 0.079). Pairwise t test of ACh EC 50 of (␣4K64T)3(␤2)2, (␣4T126L)3(␤2)2, or (␣4T126I)3(␤2)2 versus WT (␣4)3(␤2)2 nAChR revealed p values of 0.39, 0.06, and 0.01, respectively.
Combination
ACh
ACh This structure contains only two ␣4 subunits and lacks the ␣4:␣4 subunit extracellular interface, the structural domain harboring the CMPI and NS9283 binding sites. We generated an (␣4)3(␤2)2 nAChR homology model using protein superim-position, as described under "Experimental Procedures," then we performed computational docking analyses for CMPI and NS9283 in the absence of ACh (Fig. 8) . CMPI docking at the ␣4:␣4 subunit extracellular interface revealed two favorable binding modes (Fig. 8 , D and E) with CDOCKER interaction energies of Ϫ32.3 and Ϫ28.3 kcal/mol, respectively. The first CMPI orientation (Fig. 8D ) resembles the CMPI docking mode obtained using (␣4)2(␤2)3 nAChR model based on the AChBP structure (Fig. 7C ). In the second orientation, the piperidine ring of the CMPI docked deeper in the aromatic pocket, with the long axis extending toward the ␣4(Ϫ) face and CMPI maintaining close proximity (Ͻ5.0 Å) to ␣4Gln-124/␣4Thr-126/ ␣4Trp-62/␣4Lys-64. For NS9283, two docking modes with similar CDOCKER interaction energies of (Ϫ26.99 and Ϫ26.87 kcal/ mol) were predicted (Fig. 8, F and G) . In the first docking mode (Fig. 8F ) NS9283 shares the long axis location and proximity to ␣4His-116 (4.1 Å) as seen using obtained using the (␣4)2(␤2)3 nAChR model based on the AChBP structure ( Fig. 7D ). However, in the second docking mode (Fig. 8G) , the NS9283 long axis was tilted outward toward ␣4Gln-124 and ␣4Thr-126.
In view of the limitations associated with the prediction of binding modes by computational docking using homology models, it was unexpected that calculations based upon the AChBP and (␣4)2(␤2)3 nAChR structures would result in similar predictions concerning the location of bound CPMI and NS9283. However, both docking analyses predicted close proximity and interactions between CMPI or NS9283 and the amino acid residues that we identified using mutational analyses as molecular determinants for CMPI or NS9283 potentiation of the (␣4)3(␤2)2 nAChR. Furthermore, CMPI docking at the ␣4:␣4 subunit extracellular interface in the absence and presence of ACh predicted higher affinity in the absence than the presence of ACh, and the binding mode in the absence of ACh was more consistent with the effects of amino acid substitutions on CMPI potentiation of (␣4)3(␤2)2 nAChR.
Discussion
Overlapping ACh-and PAM-binding sites at the ␣4:␣4 subunit extracellular interface
In this work we used mutational analyses and two-electrode voltage-clamp recording of ACh-induced current from Xeno- Figure 8 . PAM-binding sites at the ␣4:␣4 extracellular interface in a model based on the X-ray structure of agonist-bound (␣4)2(␤2)3 nAChR. Side views showing CMPI (magenta and brown) and NS9283 (green and cherry red) docked at the ␣4:␣4 extracellular interface of (␣4)3(␤2)2 nAChR homology model based on the X-ray structure of (␣4)2(␤2)3 nAChR (PDB accession number 5KXI). This model was generated by replacing a ␤2 subunit with an ␣4 subunit from the same crystal structure as described under "Experimental Procedures." A-C, side views showing secondary structure of two ␣4 subunits (brown and yellow) with ␣-helices as cylinders and ␤-strands as ribbons. Amino acid residues contributing to the ␣4:␣4 extracellular interface are shown in stick representation colored by atom type (C, gray; O, red; N, blue) , and the four transmembrane helices of each ␣4 subunit are labeled M1-M4. Connolly surfaces of a superimposition of the two lowest energy docking solutions for CMPI and NS9283 are shown in B and C, respectively. D-G, close-up side views of the ␣4:␣4 extracellular interface showing the lowest energy docking solutions for CMPI (D and E) and NS9283 (F and G) are in stick and ball representation. For each ligand, conserved amino acid residues that make up the agonist site aromatic box and amino acid residues that significantly reduced its effects when substituted to the corresponding residue from the ␤2 subunit are shown in Connolly surface representation colored by atom charge (positive, blue; negative, red). Residues are labeled using the single letter code with those from the ␣4 (ϩ) face underlined.
pus oocytes to identify a binding site for CMPI, a PAM that is selective for the (␣4)3(␤2)2 nAChR. The stoichiometry-dependent effects of CMPI (low-sensitivity (␣4)3(␤2)2 versus highsensitivity (␣4)2(␤2)3 nAChR) and its inability to potentiate ␣3␤2 nAChR predicted a CMPI recognition site(s) at the ␣4:␣4 subunit interface that is present only in the (␣4)3(␤2)2 nAChR isoform. Because the (Ϫ) face of the ␣4 subunit is what makes the ␣4:␣4 subunit interface different from other subunit interfaces, we examined the effects of amino acid substitutions at the ␣4 subunit (Ϫ) face that project toward the ␣4:␣4 subunit interface on (␣4)3(␤2)2 nAChR potentiation by CMPI, NS9283 (another PAM with (␣4)3(␤2)2 nAChR isoform selectivity), and dFBr ((␣4)3(␤2)2/(␣4)2(␤2)3 nAChRs PAM).
A total of 15 amino acid positions, 10 within the extracellular domain and 5 within the transmembrane domain, were substituted individually to their corresponding amino acid residues in the ␣3 and/or ␤2 nAChR subunits. Within these substitutions, one position (His-116) selectively reduced potentiation by NS9283, whereas three positions (Gly-41, Lys-64, and Glu-66) selectively reduced potentiation by CMPI. Substitutions at two positions (Gln-124 and Thr-126) reduced potentiation by CMPI and NS9283. Amino acid substitution at the other nine positions did not significantly reduce potentiation by CMPI or NS9283, and none of the substitutions reported here had a significant effect on (␣4)3(␤2)2 nAChR potentiation by dFBr.
To gain further insight into the binding modes of CMPI/ NS9283, we performed computational analyses docking CMPI and NS9283 at the ␣4:␣4 subunit extracellular interface in the absence and presence of ACh bound at this interface. Our computational analyses (summarized in Fig. 7 and Fig. 8 ) predicted stable binding of CMPI and NS9283 at the ␣4:␣4 interface in the absence or presence of ACh but with different amino acid residue contacts. The functional consequences of amino acid substitutions and the predicted interactions of docked CMPI/ NS9283 with these amino acid residues establish that NS9283/ CMPI potentiate (␣4)3(␤2)2 nAChR by replacing ACh at the ␣4:␣4 subunit interface by binding to pockets that completely (NS9283) or partially (CMPI) overlap the ACh-binding site.
PAM recognition at the ␣4:␣4 extracellular interface
CMPI recognition at the ␣4:␣4 subunit extracellular interface differs from that for NS9283 and for agonists that bind at the ␣4:␣4 subunit extracellular interface, especially in regard to the role of amino acid residues in the complementary ␣4(Ϫ) face. Amino acid substitutions at positions ␣4Gly-41 and ␣4Lys-64 to the corresponding amino acid residues in the ␤2 subunit (methionine and threonine, respectively) selectively reduced potentiation by CMPI but not NS9283 or dFBr. In agreement with these findings, our computational analyses in the absence of ACh predicted CMPI binding in close proximity to ␣4Gly-41 and ␣4Lys-64 with the latter predicted to form hydrophobic interactions with the chlorobenzene and isoxazole of CMPI. This hydrophobic interaction between ␣4Lys-64 and the chlorobenzene ring appears essential for CMPI potentiation, as replacement of the chlorobenzene ring by non-substituted benzene or cyclohexane increased CMPI EC 50 by ϳ60and ϳ250-fold, respectively (31).
In contrast, amino acid substitutions at ␣4His-116 did not reduce CMPI potentiation of (␣4)3(␤2)2 nAChR, and there is no predicted interaction between ␣4His-116 and docked CMPI in the absence of ACh. ␣4His-116 is considered the main molecular determinant for (␣4)3(␤2)2 nAChR potentiation by NS9283 (17) . Indeed, amino acid substitutions at ␣4His-116, ␣4Gln-124, and ␣4Thr-126, but not any other non-conserved position within the ␣4(Ϫ) face ( Fig. 4 and Table 1 ), significantly reduced NS9283 potentiation of (␣4)3(␤2)2 nAChR, and NS9283 docked in close proximity to these amino acid residues. These results emphasize the role of ␤ strands 5 and 6 of the complementary ␣4(Ϫ) face in NS9283 binding. They contribute mainly polar amino acid residues (His/Thr/Gln), whereas ␤ strands 5 and 6 of the complementary ␤2(Ϫ) face of the ␣4:␤2 extracellular interfaces contribute mainly hydrophobic amino acid residues (Val/Phe/Leu). Furthermore, the presence of histidine at this position in the ␣4:␣4 subunit extracellular interface has been shown to impose a "steric limit" on the size of agonist (length Ͻ7 Å) that can bind at the ␣4:␣4 subunit extracellular interface (27) . This steric limit did not hinder the ability of CMPI (length 12.9 Å) to enter and bind at the ␣4:␣4 subunit extracellular interface. A simple interpretation would be that, unlike NS9283 and other agonists, CMPI occupies a binding site shifted away from ␣4His-114 and in proximity to ␣4Gly-41/␣4Ser43, consistent with the fact that substitutions at ␣4Gly-41 to larger amino acids residue (glutamate or methionine) reduced CMPI potentiation.
In addition to CMPI interactions with non-conserved amino acid residues of the ␣4(Ϫ) face, CMPI in its most favorable binding mode in the absence of ACh interacts with conserved core aromatics of the ␣4(-) and ␣4(ϩ) faces. The CMPI piperidine ring, which is a strong base and can be protonated, occupies the same position as the carbonyl group of ACh and is in close proximity to (and predicted to form H-bonds) with both the carbonyl group of ␣4Trp-154 and the hydroxyl group of ␣4Tyr-204. The methyl substitution at the pyrazole ring is predicted to form -alkyl bonds, two with the benzene and pyrrole rings of ␣4Trp-156 (␣4 (ϩ) face) and one with the benzene of ␣4Trp-62 (␣4(Ϫ) face). Indeed, the methyl substitution enhanced the potency of CMPI by ϳ7-fold over non-substituted pyrazole (H instead of CH 3 ), and replacement of the methyl by an ethyl group further enhanced CMPI potency as an ␣4␤2 nAChR potentiator (31) . We predict that longer alkyl substituents would further enhance the hydrophobic interaction of CMPI with these core aromatic residues in the ␣4:␣4 subunit interface.
Relevance to allosteric modulation of nAChR
In contrast to the canonical ␣4:␤2 agonist-binding sites, the structural features, ligand-binding, and functional contributions of the non-canonical ␣4:␣4 agonist-binding site are still under ongoing investigation. Nevertheless, published studies of the pharmacology of high and low sensitivity ␣4␤2 nAChRs have established that the ␣4:␣4 agonist-binding site is structurally and functionally distinct from the ␣4:␤2 agonist-binding sites and that the ␣4:␤2 agonist-binding sites of the (␣4)3(␤2)2 and (␣4)2(␤2)3 nAChR are functionally non-equivalent (17, (25) (26) (27) . ACh binds to the ␣4:␤2 agonist-binding sites of (␣4)2(␤2)3 and (␣4)3(␤2)2 nAChRs with similar apparent affinity (EC 50 ϳ1 M). However, ACh occupancy of the two ␣4:␤2 agonist-binding sites of the (␣4)2(␤2)3 but not the (␣4)3(␤2)2 nAChR is sufficient for full receptor activation. In the (␣4)3(␤2)2 nAChR, full ACh occupancy of the two ␣4:␤2 agonist-binding sites results in only ϳ20% of full activation with full activation achieved at higher ACh concentrations (EC 50 ϳ100 M) when the ␣4:␣4 agonist-binding site is occupied. Using this mechanistic model, the effect of CMPI on AChinduced responses of (␣4)3(␤2)2 nAChR activation can be viewed as a co-agonistic or allosteric effect. In both cases, CMPI occupies the ␣4:␣4 extracellular interface with much higher affinity than ACh and renders the ␣4:␤2 agonist-binding sites of the (␣4)3(␤2)2 nAChR functionally equivalent to the ␣4:␤2 agonist-binding sites of the (␣4)2(␤2)3 nAChR (i.e. ACh binding at the ␣4:␤2 agonist-binding sites results in full activation of (␣4)3(␤2)2 nAChR). At macroscopic current levels, CMPI potentiation of (␣4)3(␤2)2 nAChR was characterized by an increase of ACh potency with no effect on the maximum AChinduced current (Fig. 6 ). This pharmacological profile supports an allosteric mechanism for CMPI potentiation. Nevertheless, further studies using patch-clamp and single-channel recording are required to further clarify the mechanism of CMPI potentiation of (␣4)3(␤2)2 nAChR.
Despite binding with high affinities at the ␣4:␣4 interface, CMPI and NS9283 lack agonist activity in wild-type (␣4)3(␤2)2 nAChRs. Their binding at the ␣4:␣4 extracellular interface potentiates current responses triggered by ACh binding at the ␣4:␤2 agonist-binding sites. The higher affinity of CMPI and NS9283 for the ␣4:␣4 versus ␣4:␤2 interface could explain their lack of agonist activity, as binding of at least two agonist molecules is required for channel gating (25) . Indeed, NS9283 acted as an agonist in (␣4)3(␤2)2 nAChRs mutated to contain two ␣4:␣4-like agonist-binding sites (17) . Although more studies are needed to fully understand the pharmacology of the ␣4:␣4 drug-binding sites, the work presented here provides comprehensive analyses of the role of the ␣4:␣4 extracellular interface in the allosteric modulation of ␣4␤2 nAChRs. The results of this study will facilitate the design and development of novel ␣4␤2 nAChR-selective ligands with potential experimental and clinical applications.
Experimental procedures
Materials CMPI was a generous gift from Drs. Stefan McDonough and Alessandro Boezio (Amgen Inc. Cambridge, MA; Ref. 30 ). dFBr and NS9283 were from TOCRIS Bioscience R&D (Minneapolis, MN). Collagenase type 2 was from Worthington Biomedical, Lakewood, NJ. Acetylcholine chloride and other chemicals were purchased from Sigma unless otherwise indicated in the text.
cDNA plasmids and site-directed mutagenesis
pSP64 poly(A) plasmids with cDNA encoding for human ␣4 or ␤2 nAChR subunit were generously provided by Dr. Jon Lindstrom (University of Pennsylvania). Point mutations were introduced into plasmid expression vectors coding for the ␣4 nAChR subunit using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) then confirmed by DNA sequencing (GENEWIZ, LLC., South Plainfield, NJ). For each point mutation within ␣4, two custom-designed complimentary oligos containing the desired mutation were ordered from Integrated DNA Technologies (Coralville, IA). Amino acid numbers are based on the mature ␣4 subunit; add 28 to convert to amino acid numbering starting from the transitional N terminus (methionine 1) of the ␣4 subunit.
Receptor expression in Xenopus oocytes
cDNA plasmids of wild-type (WT) and mutant nAChR subunits were linearized with AseI (h␣4) and PvuII (h␤2), then cRNA transcripts suitable for oocytes expression were prepared from linearized plasmid using SP6 mMESSAGE mMACHINE high yield capped RNA transcription kits (Ambion) following the manufacturer's protocol. RNA concentration was estimated from the A 260 (with 260/280 ratio Ͼ1.9) and mixed at ratios 8␣:1␤ or 1␣:8␤ to express nAChRs with subunit stoichiometries of 3␣:2␤ or 2␣:3␤, respectively. The final concentration of the subunits RNA mixture was adjusted to 100 -200 ng/l with nuclease-free water, and oocytes were injected with a volume containing 5-20 ng of cRNA.
Oocytes-positive female X. laevis were purchased from NASCO (Fort Atkinson, WI), and ovarian lobules were harvested surgically following animal use protocols approved by the Texas A&M Health Sciences Center Institutional Animals Care and Use Committee. The lobules were treated with 3 mg/ml collagenase type 2 (Worthington Biomedical) with gentle shaking for 3 h at room temperature in Ca ϩ2 -free OR2 buffer (85 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 5 mM HEPES, pH 7.6). Stage V and VI oocytes were selected, injected with cRNA, and incubated at 18°C in ND96-gentamicin buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, 50 g/ml gentamicin, pH 7.6) for 24 -72 h to allow receptor expression.
Electrophysiological recording
A standard two-electrode voltage-clamp technique was used as described previously (30, 33) to acquire whole cell current from oocytes expressing WT or a mutant nAChR in response to drug(s) application. Xenopus oocytes were voltage-clamped at Ϫ50 mV using Oocyte Clamp OC-725C (Warner Instruments) in a custom-made small recording chamber and under continuous perfusion with recording buffer (100 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 0.8 mM MgCl 2 , 1 mM EGTA, 10 mM HEPES, pH 7.5). An automated perfusion system made up of glass reservoirs and Teflon tubing (Warner Instruments) was used to control recording chamber perfusion and drug application. Each recording run included 3-6 drug applications (10 s each) separated by 90-s wash intervals unless otherwise specified in the figure legends, and oocytes were washed for 3-5 min between runs. Each drug concentration was tested at least two times per oocyte and repeated on a number of oocytes (N) as specified in Tables 1-3 . Current traces were digitized at 50 Hz and analyzed, and peak current amplitudes in response to drug applications were quantified using Digidata 1550A interface/ pCLAMP 10.4 software (Molecular Devices). CMPI and NS9283 were prepared as 10 mM stock solution in DMSO, and dFBr was prepared as 5 mM stock solution in water. Stock solutions were stored at Ϫ20°C and diluted to final concentrations in recording buffer on the day of experiments. At the highest concentration tested, DMSO was present at 0.1%, which had no effect on ACh responses.
Data analysis
Data analyses, parameter calculations, and statistical analyses were performed using Excel (Microsoft Corp.) and Sigmaplot v11 (Systat Software Inc.). For concentration-dependent potentiation of ACh-induced currents by CMPI, peak current amplitudes in response to co-applications of CMPI with 10 M ACh were normalized to the peak current amplitude elicited by 10 M ACh alone within same recording run. For ACh concentration-response curves in the absence or presence of CMPI, peak current amplitudes in response to co-applications of increasing concentrations of ACh (Ϯ1 M CMPI) were normalized to the peak current amplitude elicited by 1 mM ACh alone within same recording run. Replicas from the same oocyte were combined (average Ϯ S.D.; the oocyte with S.D. of Ͼ30% of its average was rejected), and data (average Ϯ S.E.) from N oocytes were plotted and fit to a 3-parameter Hill equation,
where Ix is the normalized ACh current in the presence of CMPI at concentration x, I max is the maximum potentiation of current, h is the Hill coefficient, and EC 50 is the CMPI concentration producing 50% of maximal potentiation. For CMPI enhancement, I 0 ϭ 100, and the probability (P) that the I max differs from no potentiation (I max ϭ 100) was analyzed using one-way analysis of variance with the Holm-Sidak test and is reported in Table 2 . For ACh concentration response, I 0 ϭ 0, and the probability (P) that the ACh EC 50 in the presence of CMPI differs from ACh EC 50 in the absence of CMPI was analyzed by the t test and is reported in Table 3 .
Molecular modeling
Homology modeling and docking simulations (CDOCKER) were performed using the Discovery Studio 2017 molecular modeling package from Accelrys. Homology models based on two different X-ray crystallographic structures were constructed as follows.
A homology model of the extracellular domain of the human (␣4)3(␤2)2 nAChR was constructed from the structure of the Lymnaea stagnalis AChBP crystallized with carbamylcholine (PDB accession number 1UV6; Ref. 37) by replacing subunits A, C, and E with ␣4 residues and B and D with ␤2 residues. The computer-generated alignment was checked to ensure insertions/deletions occurred outside secondary structure motifs (␣-helices or ␤-sheets). The alignment between ␣4 and AChBP began with ␣4His-9 (amino acid numbering is for mature protein according to the X-ray structure of human (␣4)2(␤2)3 nAChRs (PDB accession number 5KXI; add 26 to obtain amino acid numbers starting from the translational N terminus) and with AChBP L1 and required ␣4 insertions of residues Asn-31, Asp-78, Tyr-79, Gly-105, and Phe-144 and an AChBP deletion at residue Tyr-168. The alignment between ␤2 and AChBP began with ␤2 Asp-2 (amino acid numbering is for mature protein; add 25 to obtain amino acid numbers starting from the translational N terminus) and with AChBP L1 and required ␤2 insertions of residues Lys-19, Lys-20, Gly-27, Phe-74, Asp-75, Asp-99, and Phe-13 and AChBP deletions of residues Ser-162, Ser-186, Cys-187, and Cys-188. Carbamylcholine molecules were placed into the two ␣4:␤2 agonist sites and the ␣4:␣4 interface site in orientations approximating that of carbamylcholine in the crystal structure, and the model was minimized to Ϫ2.30 ϫ 10 4 kcal/mol. The carbamylcholine molecule was removed from the ␣4-␣4 interface site before docking.
Additional docking on the 1UV6.PDB-based model was performed after first identifying (by docking) the preferred binding site for acetylcholine, placing an acetylcholine molecule in the ␣4:␣4 binding site, and minimizing (Ϫ22,937 kcal/mol final energy). A 12 Å binding-site sphere was used with its center between ␣4Gln-122 and ␣4Cys-198, and eight randomly positioned CMPI and NS9283 molecules were docked within this binding-site sphere using the same parameters described above.
A homology model of (␣4)3(␤2)2 nAChR was constructed from the human (␣4)2(␤2)3 nAChR crystal structure (PDB accession number 5KXI; Ref. 3) by using the "Superimpose Proteins" tool to superimpose a copy of the ␣4 subunit, designated A, onto the ␤2 subunit, designated B. This was necessary as the 5KXI.PDB structure does not contain an ␣4-␣4 interface which is the focus of this work. The superimposition was accomplished by minimizing the distances between pairs of tethered ␣-carbons of 4 conserved residues: ␤2Pro-219 tethered with ␣4Pro-227 (M1); ␤2Trp-57 with ␣4Trp-62 (aromatic box); ␤2Cys-130 with ␣4Cys-135 (Cys-loop); ␤2Gly-116 with ␣4Gly-121 (agonist site loop E). Once the copied ␣4 was superimposed over the ␤2-B subunit's position, the ␤2-B subunit was deleted, and the new ␣4-B was inserted into the structure. This method was used in an attempt to preserve as much as possible the crystal structure of the ␣4␤2 nAChR. The nicotine molecule originally between subunits A (␣4) and B (␤2) was left in place in the homology model now at the ␣4-␣4 interface, and minimal energy minimization (5 cycles) was performed to reduce any strain interactions due to the subunit replacement (initial energy, 1.78 ϫ 10 10 kcal/mol; final energy, Ϫ8.39 ϫ 10 4 kcal/ mol; for reference, 5KXI.PDB had initial energy of Ϫ5.29 ϫ 10 4 kcal/mol and 10 minimization cycles produced Ϫ8.46 ϫ 10 4 kcal/mol). The nicotine molecule was removed from the ␣4:␣4 interface site before docking. Initial docking studies with CMPI yielded no solutions with favorable interaction energies (lowest energy solutions were ϳϪ1 kcal/mol). To allow CMPI to dock within the ␣4:␣4 binding site, side chains of Lys-64, Gln-124, and Thr-126 on the minus face were reoriented to mimic the 1UV6.PDB-based homology model that readily docked CMPI.
For docking, eight structurally different molecules of CMPI and NS9283 were seeded together in random orientations and used to dock to the ␣4:␣4 interface "agonist" sites for each model using CDOCKER. CDOCKER is a CHARMm-based molecular dynamics simulated annealing program that treats the ligand as fully flexible while maintaining a rigid receptor (39, 40) . A binding-site sphere of radius 12 Å was used that was centered on the location of carbamylcholine or nicotine in the respective models. We configured the docking parameters so that each of the 8 seeded ligands was subjected to 40ϩ hightemperature molecular dynamic-induced structural alterations and 40ϩ random translation/rotation reorientations, producing a total of 1600ϩ attempts at docking. For each attempt, the ligand and the amino acids within the binding sphere were subjected to simulated annealing, and a full potential final minimization step from which the ligand-receptor interaction energies was calculated. The orientation of the ligand and the calculated interaction energies were collected for the 50 lowest energy solutions for each seeded ligand.
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